Do analysts recommend AGPU or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axe Compute 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Predictive Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer POAI or TCX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tucows 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer VVPR or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivopower International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, VVPR or POAI?

Predictive Oncology has higher revenue and earnings than Vivopower International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivopower International $61K 607.87 -$12.79M N/A N/A Predictive Oncology $1.66M 21.92 -$12.66M -$13.50 N/A

Do analysts rate POAI or VIVO?

VivoPower PLC Ordinary Shares has a consensus price target of $10.00, indicating a potential upside of 284.62%. Given VivoPower PLC Ordinary Shares' stronger consensus rating and higher probable upside, analysts clearly believe VivoPower PLC Ordinary Shares is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoPower PLC Ordinary Shares 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, POAI or VIVO?

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Predictive Oncology $1.66M 21.92 -$12.66M -$13.50 N/A VivoPower PLC Ordinary Shares $60K 542.97 -$12.79M N/A N/A

Do analysts recommend POAI or XLAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 D. Boral ARC Acquisition I 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, POAI or XLAB?

D. Boral ARC Acquisition I has higher revenue and earnings than Predictive Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Predictive Oncology $1.66M 21.92 -$12.66M -$13.50 N/A D. Boral ARC Acquisition I $14.82M 2.10 N/A N/A N/A

Predictive Oncology (POAI) Competitors

$9.66 -1.09 (-10.14%)

As of 10/13/2026

Compare

POAI vs. AGPU, TCX, VVPR, VIVO, and XLAB

Should you buy Predictive Oncology stock or one of its competitors? Predictive Oncology's main competitors and comparable companies include Axe Compute (AGPU), Tucows (TCX), Vivopower International (VVPR), VivoPower PLC Ordinary Shares (VIVO), and D. Boral ARC Acquisition I (XLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "internet services & infrastructure" industry.

How does Predictive Oncology compare to Axe Compute?

Axe Compute (NASDAQ:AGPU) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Predictive Oncology has a net margin of -5,065.23% compared to Axe Compute's net margin of -7,769.61%. Predictive Oncology's return on equity of -732.73% beat Axe Compute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axe Compute	-7,769.61%	-1,606.56%	-355.39%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

9.0% of Axe Compute shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Axe Compute has a beta of 3.66, suggesting that its stock price is 266% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Predictive Oncology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Predictive Oncology has higher revenue and earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120K	933.00	-$233.10M	-$5.75	N/A
Predictive Oncology	$1.66M	21.92	-$12.66M	-$13.50	N/A

In the previous week, Axe Compute had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for Axe Compute and 0 mentions for Predictive Oncology. Axe Compute's average media sentiment score of 1.88 beat Predictive Oncology's score of 0.75 indicating that Axe Compute is being referred to more favorably in the media.

Company	Overall Sentiment
Axe Compute	Very Positive
Predictive Oncology	Positive

Summary

Axe Compute beats Predictive Oncology on 8 of the 13 factors compared between the two stocks.

How does Predictive Oncology compare to Tucows?

Predictive Oncology (NASDAQ:POAI) and Tucows (NASDAQ:TCX) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Tucows has a net margin of -21.20% compared to Predictive Oncology's net margin of -5,065.23%. Tucows' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Tucows	-21.20%	N/A	-9.48%

Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Tucows has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 73.6% of Tucows shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 8.4% of Tucows shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Predictive Oncology has higher earnings, but lower revenue than Tucows. Tucows is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	21.92	-$12.66M	-$13.50	N/A
Tucows	$390.30M	0.27	-$75.82M	-$7.53	N/A

In the previous week, Tucows had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Tucows and 0 mentions for Predictive Oncology. Tucows' average media sentiment score of 1.27 beat Predictive Oncology's score of 0.75 indicating that Tucows is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Positive
Tucows	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tucows	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tucows beats Predictive Oncology on 10 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to Vivopower International?

Vivopower International (NASDAQ:VVPR) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Predictive Oncology has higher revenue and earnings than Vivopower International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivopower International	$61K	607.87	-$12.79M	N/A	N/A
Predictive Oncology	$1.66M	21.92	-$12.66M	-$13.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivopower International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Predictive Oncology's average media sentiment score of 0.75 beat Vivopower International's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivopower International	Neutral
Predictive Oncology	Positive

Vivopower International has a beta of -1.65, meaning that its share price is 265% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

15.8% of Vivopower International shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 9.1% of Vivopower International shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vivopower International has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Vivopower International's return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivopower International	N/A	N/A	N/A
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

Vivopower International beats Predictive Oncology on 7 of the 11 factors compared between the two stocks.

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Predictive Oncology (NASDAQ:POAI) and VivoPower PLC Ordinary Shares (NASDAQ:VIVO) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, VivoPower PLC Ordinary Shares has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

VivoPower PLC Ordinary Shares has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. VivoPower PLC Ordinary Shares' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
VivoPower PLC Ordinary Shares	N/A	N/A	N/A

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	21.92	-$12.66M	-$13.50	N/A
VivoPower PLC Ordinary Shares	$60K	542.97	-$12.79M	N/A	N/A

VivoPower PLC Ordinary Shares has a consensus price target of $10.00, indicating a potential upside of 284.62%. Given VivoPower PLC Ordinary Shares' stronger consensus rating and higher probable upside, analysts clearly believe VivoPower PLC Ordinary Shares is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoPower PLC Ordinary Shares	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, VivoPower PLC Ordinary Shares had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for VivoPower PLC Ordinary Shares and 0 mentions for Predictive Oncology. VivoPower PLC Ordinary Shares' average media sentiment score of 1.43 beat Predictive Oncology's score of 0.75 indicating that VivoPower PLC Ordinary Shares is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Positive
VivoPower PLC Ordinary Shares	Positive

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 15.8% of VivoPower PLC Ordinary Shares shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 9.1% of VivoPower PLC Ordinary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

VivoPower PLC Ordinary Shares beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to D. Boral ARC Acquisition I?

Predictive Oncology (NASDAQ:POAI) and D. Boral ARC Acquisition I (NASDAQ:XLAB) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

D. Boral ARC Acquisition I has higher revenue and earnings than Predictive Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	21.92	-$12.66M	-$13.50	N/A
D. Boral ARC Acquisition I	$14.82M	2.10	N/A	N/A	N/A

9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, D. Boral ARC Acquisition I had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for D. Boral ARC Acquisition I and 0 mentions for Predictive Oncology. D. Boral ARC Acquisition I's average media sentiment score of 1.41 beat Predictive Oncology's score of 0.75 indicating that D. Boral ARC Acquisition I is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Positive
D. Boral ARC Acquisition I	Positive

D. Boral ARC Acquisition I has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. D. Boral ARC Acquisition I's return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
D. Boral ARC Acquisition I	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
D. Boral ARC Acquisition I	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

D. Boral ARC Acquisition I beats Predictive Oncology on 7 of the 10 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	IT Services Industry	Technology Sector	NASDAQ Exchange
Market Cap	$32.79M	$11.52B	$30.14B	$12.91B
Dividend Yield	N/A	2.83%	2.76%	22.89%
P/E Ratio	-0.72	13.77	78.57	25.25
Price / Sales	19.70	49.96	581.85	78.51
Price / Cash	N/A	42.86	49.48	53.04
Price / Book	-21.00	9.08	7.72	5.92
Net Income	-$12.66M	$280.14M	$768.63M	$381.16M
7 Day Performance	-21.40%	-3.73%	-4.34%	-4.32%
1 Month Performance	-13.52%	-7.02%	-3.54%	-7.19%
1 Year Performance	-28.87%	12.16%	163.10%	-4.99%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	N/A	$9.66 -10.1%	N/A	-20.2%	$32.79M	$1.66M	N/A	30	Gap Down
AGPU Axe Compute	1.0902 of 5 stars	$11.65 -5.2%	N/A	N/A	$135.29M	$120K	N/A	14	Positive News
TCX Tucows	0.2323 of 5 stars	$9.16 -2.4%	N/A	-47.5%	$102.44M	$394.44M	N/A	759	News Coverage
VVPR Vivopower International	N/A	$3.29 -2.1%	N/A	-37.8%	$41.21M	$61K	N/A	240	Gap Down
VIVO VivoPower PLC Ordinary Shares	1.6039 of 5 stars	$3.24 -1.5%	$10.00 +208.6%	N/A	$40.60M	$60K	N/A	41	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, VVPR, VIVO, and XLAB

How does Predictive Oncology compare to Axe Compute?

Summary

How does Predictive Oncology compare to Tucows?

Summary

How does Predictive Oncology compare to Vivopower International?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Summary

How does Predictive Oncology compare to D. Boral ARC Acquisition I?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, VVPR, VIVO, and XLAB

How does Predictive Oncology compare to Axe Compute?

Is AGPU or POAI more profitable?

Do institutionals and insiders have more ownership in AGPU or POAI?

Which has more volatility and risk, AGPU or POAI?

Do analysts recommend AGPU or POAI?

Which has stronger earnings and valuation, AGPU or POAI?

Does the media refer more to AGPU or POAI?

Summary

How does Predictive Oncology compare to Tucows?

Is POAI or TCX more profitable?

Which has more risk & volatility, POAI or TCX?

Do insiders & institutionals hold more shares of POAI or TCX?

Which has preferable valuation & earnings, POAI or TCX?

Does the media prefer POAI or TCX?

Do analysts prefer POAI or TCX?

Summary

How does Predictive Oncology compare to Vivopower International?

Which has higher valuation & earnings, VVPR or POAI?

Do analysts prefer VVPR or POAI?

Does the media refer more to VVPR or POAI?

Which has more risk and volatility, VVPR or POAI?

Do insiders and institutionals hold more shares of VVPR or POAI?

Is VVPR or POAI more profitable?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Which has more volatility and risk, POAI or VIVO?

Is POAI or VIVO more profitable?

Which has stronger earnings and valuation, POAI or VIVO?

Do analysts rate POAI or VIVO?

Does the media favor POAI or VIVO?

Do institutionals and insiders have more ownership in POAI or VIVO?

Summary

How does Predictive Oncology compare to D. Boral ARC Acquisition I?

Which has preferable earnings and valuation, POAI or XLAB?

Do insiders & institutionals believe in POAI or XLAB?

Does the media refer more to POAI or XLAB?

Is POAI or XLAB more profitable?

Do analysts recommend POAI or XLAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools